BUZZ-Intra-Cellular公司治疗抑郁症的药物在后期试验中达到主要目标

Reuters06-18

((自动化翻译由路透提供，请见免责声明 ))

6月18日 - ** 制药商Intra-Cellular Therapies 股价最高上涨11.1%，达到近两个月的新高76.50美元。

** 该公司的药物lumperone显示，与安慰剂相比，抑郁症的严重程度发生了变化，达到了后期试验的主要目标 (link)

** ITCI预计将于2024年下半年向美国FDA提交申请，寻求扩大批准鲁马培龙作为治疗重度抑郁症的药物

** 该药名为Calypta，已被批准用于治疗精神分裂症和与双相情感障碍类型相关的抑郁发作

** 年初至今，股价上涨 6.6

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2444432107?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-06-18 23:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2444432107","market":"us","top_or_hot":-1,"title":"BUZZ-Intra-Cellular公司治疗抑郁症的药物在后期试验中达到主要目标","media":"Reuters","content":"<html><body><p>((自动化翻译由路透提供，请见免责声明 ))</p><p>    6月18日 - ** 制药商Intra-Cellular Therapies   股价最高上涨11.1%，达到近两个月的新高76.50美元。 </p><p>** 该公司的药物lumperone显示，与安慰剂相比，抑郁症的严重程度发生了变化，达到了后期试验的主要目标 (link) </p><p>** ITCI预计将于2024年下半年向美国FDA提交申请，寻求扩大批准鲁马培龙作为治疗重度抑郁症 的药物</p><p>** 该药名为Calypta，已 被批准用于治疗精神分裂症和与双相情感障碍类型相关的抑郁发作</p><p>** 年初至今，股价上涨 6.6 </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Intra-Cellular公司治疗抑郁症的药物在后期试验中达到主要目标</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Intra-Cellular公司治疗抑郁症的药物在后期试验中达到主要目标\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-18 23:31 北京时间&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>((自动化翻译由路透提供，请见免责声明 ))    6月18日 - ** 制药商Intra-Cellular Therapies   股价最高上涨11.1%，达到近两个月的新高76.50美元。 ** 该公司的药物lumperone显示，与安慰剂相比，抑郁症的严重程度发生了变化，达到了后期试验的主要目标 (link) ** ITCI预计将于2024年下半年向美国FDA提交申请，寻求扩大批准鲁马培龙...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富兰克林生物科技新领域基金A (acc)","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2444432107","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2444432107","pubTimestamp":1718724700,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"((自动化翻译由路透提供，请见免责声明 ))    6月18日 - ** 制药商Intra-Cellular Therapies   股价最高上涨11.1%，达到近两个月的新高76.50美元。 ** 该公司的药物lumperone显示，与安慰剂相比，抑郁症的严重程度发生了变化，达到了后期试验的主要目标 (link) ** ITCI预计将于2024年下半年向美国FDA提交申请，寻求扩大批准鲁马培龙作为治疗重度抑郁症 的药物** 该药名为Calypta，已 被批准用于治疗精神分裂症和与双相情感障碍类型相关的抑郁发作** 年初至今，股价上涨 6.6","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4007":"制药","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","ITCI":"Intra-Cellular Therapies Inc.","BUZZ":"VanEck Social Sentiment ETF","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD"},"translate_title":"BUZZ-Intra-Cellular drug for depression hits main goal in late-stage trial","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BUZZ":1,"ITCI":0.9},"content_text":"((自动化翻译由路透提供，请见免责声明 ))    6月18日 - ** 制药商Intra-Cellular Therapies   股价最高上涨11.1%，达到近两个月的新高76.50美元。 ** 该公司的药物lumperone显示，与安慰剂相比，抑郁症的严重程度发生了变化，达到了后期试验的主要目标 (link) ** ITCI预计将于2024年下半年向美国FDA提交申请，寻求扩大批准鲁马培龙作为治疗重度抑郁症 的药物** 该药名为Calypta，已 被批准用于治疗精神分裂症和与双相情感障碍类型相关的抑郁发作** 年初至今，股价上涨 6.6","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2444432107"}